Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in antiviral chemotherapy.

M A McKinlay1, M J Otto

  • 1Virology Section, Sterling-Winthrop Research Institute, Rensselaer, New York.

Infectious Disease Clinics of North America
|June 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-<i>κ</i>B signaling by degrading TRAF2-associated cIAP1 in cancer cells.

Cell death discovery·2017
Same author

A rapid microtiter assay for duck hepatitis virus reverse transcriptase.

Methods in molecular medicine·2011
Same author

Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.

Antimicrobial agents and chemotherapy·2005
Same author

Recent advances in the treatment of rhinovirus infections.

Current opinion in pharmacology·2002
Same author

Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.

Bioorganic & medicinal chemistry letters·2000
Same author

Pleconaril. A broad spectrum antipicornaviral agent.

Advances in experimental medicine and biology·1999
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

New antiviral agents show promise for treating viral diseases. Advances in technology aid in discovering virus-specific inhibitors for conditions from the common cold to AIDS.

Area of Science:

  • Virology
  • Drug Discovery
  • Biotechnology

Background:

  • Viral diseases pose significant health challenges, necessitating novel therapeutic strategies.
  • Antiviral research has historically faced challenges in identifying effective and specific treatments.
  • The need for effective treatments spans a wide spectrum of viral infections, including common viral infections and more severe conditions like Acquired Immunodeficiency Syndrome (AIDS).

Purpose of the Study:

  • To explore the promising prospects for developing new antiviral agents.
  • To highlight the role of technological advancements in antiviral drug discovery.
  • To emphasize the importance of virus-specific targets for effective antiviral therapies.

Main Methods:

  • Application of advanced technologies including X-ray crystallography, genetic engineering, and monoclonal antibody development.

Related Experiment Videos

  • Identification of virus-specific processes and proteins crucial for viral replication.
  • Development of rapid diagnostic tests for viral diseases.

    • Main Results:

    • Technological innovations are accelerating the discovery of novel antiviral agents.
    • The identification of essential virus-specific processes provides viable targets for drug development.
    • Rapid advancements in diagnostic testing are expected to improve the clinical application of new antivirals.

    Conclusions:

    • The development of new antiviral agents for a range of viral diseases is highly promising.
    • Targeting virus-specific processes with molecular inhibitors is a viable and effective strategy.
    • Integrated approaches combining drug discovery and diagnostics will enhance the management of viral infections.